SEC Form 4 · accession 0001104659-16-106427
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adrian Adams
Officer — Chief Executive Officer · Director
Period of report
Mar 17, 2016
Accepted (ET)
Mar 18, 2016 · 8:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF1 | Mar 17, 2016 | A | 124,342 | $0.00 | A | 3,069,230 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $3.80 | Mar 17, 2016 | A | 105,251 | A | — | Mar 17, 2026 | Common Shares, without par value | 105,251 | 105,251 | D |
Explanation of responses
- F1Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Long-Term Incentive Plan, which vest ratably over three years commencing on the anniversary of the date-of-grant.
- F2The options vest in equal tranches on a monthly basis over a 4-year period beginning on April, 17, 2016.